Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T20:27:38.792Z.
Calculation as of: 2026-10-06T20:27:38.792Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4aebd5d53392a49c55eaf762d12be1f1a7ff494d091d9ceadcd34fda62bcd254
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
PMV Pharmaceuticals, Inc.
Market Cap
$85.86M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.27M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.13M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.85M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.96M
Operating Cash Flow Yield
30.38%
TTM Avg
24.07%
3Y Avg
48.72%
5Y Avg
43.33%
Market Cap
$82.59M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.53M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.47M
Operating Cash Flow Yield
N/A
TTM Avg
5.92%
3Y Avg
6.70%
5Y Avg
6.29%
Market Cap
$89.44M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $85.86M | N/A | N/A | N/A | N/A |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 30.38% | 24.07% | 48.72% | 43.33% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | N/A | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | N/A | 5.92% | 6.70% | 6.29% |
| electroCore, Inc. (ECOR)vs › | $89.44M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
